Global Cancer Biosimilar Monoclonal Antibodies Market Insights, Forecast to 2031

TABLE OF CONTENTS

1 Report Overview

• 1.1 Study Scope
• 1.2 Market Analysis by Type
  • 1.2.1 Global Cancer Biosimilar Monoclonal Antibodies Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
  • 1.2.2 Mouse Derived Monoclonal Antibody
  • 1.2.3 Human Mouse Chimeric Monoclonal Antibody
  • 1.2.4 Human Derived Monoclonal Antibody
  • 1.2.5 Fully Human Derived Monoclonal Antibody
• 1.3 Market by Application
  • 1.3.1 Global Cancer Biosimilar Monoclonal Antibodies Market Share by Application: 2020 VS 2024 VS 2031
  • 1.3.2 Solid Tumor Treatment
  • 1.3.3 Hematological System Tumor Treatment
  • 1.3.4 Combination Therapy
• 1.4 Assumptions and Limitations
• 1.5 Study Objectives
• 1.6 Years Considered

2 Global Growth Trends

• 2.1 Global Cancer Biosimilar Monoclonal Antibodies Market Perspective (2020-2031)
• 2.2 Global Cancer Biosimilar Monoclonal Antibodies Growth Trends by Region
  • 2.2.1 Global Cancer Biosimilar Monoclonal Antibodies Market Size by Region: 2020 VS 2024 VS 2031
  • 2.2.2 Cancer Biosimilar Monoclonal Antibodies Market Size by Region (2020-2031)
• 2.3 Cancer Biosimilar Monoclonal Antibodies Market Dynamics
  • 2.3.1 Cancer Biosimilar Monoclonal Antibodies Industry Trends
  • 2.3.2 Cancer Biosimilar Monoclonal Antibodies Market Drivers
  • 2.3.3 Cancer Biosimilar Monoclonal Antibodies Market Challenges
  • 2.3.4 Cancer Biosimilar Monoclonal Antibodies Market Restraints

3 Competition Landscape by Key Players

• 3.1 Global Revenue Cancer Biosimilar Monoclonal Antibodies by Players
  • 3.1.1 Global Cancer Biosimilar Monoclonal Antibodies Revenue by Players (2020-2025)
  • 3.1.2 Global Cancer Biosimilar Monoclonal Antibodies Revenue Market Share by Players (2020-2025)
• 3.2 Global Cancer Biosimilar Monoclonal Antibodies Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
• 3.3 Global Key Players of Cancer Biosimilar Monoclonal Antibodies, Ranking by Revenue, 2023 VS 2024 VS 2025
• 3.4 Global Market Concentration Ratio
  • 3.4.1 Global Cancer Biosimilar Monoclonal Antibodies Market Concentration Ratio (CR5 and HHI)
  • 3.4.2 Global Top 10 and Top 5 Companies by Cancer Biosimilar Monoclonal Antibodies Revenue in 2024
• 3.5 Global Key Players of Cancer Biosimilar Monoclonal Antibodies Head office and Area Served
• 3.6 Global Key Players of Cancer Biosimilar Monoclonal Antibodies, Product and Application
• 3.7 Global Key Players of Cancer Biosimilar Monoclonal Antibodies, Date of Enter into This Industry
• 3.8 Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Type

• 4.1 Global Cancer Biosimilar Monoclonal Antibodies Historic Market Size by Type (2020-2025)
• 4.2 Global Cancer Biosimilar Monoclonal Antibodies Forecasted Market Size by Type (2026-2031)

5 Breakdown Data by Application

• 5.1 Global Cancer Biosimilar Monoclonal Antibodies Historic Market Size by Application (2020-2025)
• 5.2 Global Cancer Biosimilar Monoclonal Antibodies Forecasted Market Size by Application (2026-2031)

6 North America

• 6.1 North America Cancer Biosimilar Monoclonal Antibodies Market Size (2020-2031)
• 6.2 North America Market Size by Type
  • 6.2.1 North America Cancer Biosimilar Monoclonal Antibodies Market Size by Type (2020-2031)
  • 6.2.2 North America Cancer Biosimilar Monoclonal Antibodies Market Share by Type (2020-2031)
• 6.3 North America Market Size by Application
  • 6.3.1 North America Cancer Biosimilar Monoclonal Antibodies Market Size by Application (2020-2031)
  • 6.3.2 North America Cancer Biosimilar Monoclonal Antibodies Market Share by Application (2020-2031)
• 6.4 North America Market Size by Country
  • 6.4.1 North America Cancer Biosimilar Monoclonal Antibodies Market Size by Country: 2020 VS 2024 VS 2031
  • 6.4.2 North America Cancer Biosimilar Monoclonal Antibodies Market Size by Country (2020-2031)
  • 6.4.3 United States
  • 6.4.4 Canada

7 Europe

• 7.1 Europe Cancer Biosimilar Monoclonal Antibodies Market Size (2020-2031)
• 7.2 Europe Market Size by Type
  • 7.2.1 Europe Cancer Biosimilar Monoclonal Antibodies Market Size by Type (2020-2031)
  • 7.2.2 Europe Cancer Biosimilar Monoclonal Antibodies Market Share by Type (2020-2031)
• 7.3 Europe Market Size by Application
  • 7.3.1 Europe Cancer Biosimilar Monoclonal Antibodies Market Size by Application (2020-2031)
  • 7.3.2 Europe Cancer Biosimilar Monoclonal Antibodies Market Share by Application (2020-2031)
• 7.4 Europe Market Size by Country
  • 7.4.1 Europe Cancer Biosimilar Monoclonal Antibodies Market Size by Country: 2020 VS 2024 VS 2031
  • 7.4.2 Europe Cancer Biosimilar Monoclonal Antibodies Market Size by Country (2020-2025)
  • 7.4.3 Germany
  • 7.4.4 France
  • 7.4.5 U.K.
  • 7.4.6 Italy
  • 7.4.7 Russia
  • 7.4.8 Nordic Countries

8 China

• 8.1 China Cancer Biosimilar Monoclonal Antibodies Market Size (2020-2031)
• 8.2 China Market Size by Type
  • 8.2.1 China Cancer Biosimilar Monoclonal Antibodies Market Size by Type (2020-2031)
  • 8.2.2 China Cancer Biosimilar Monoclonal Antibodies Market Share by Type (2020-2031)
• 8.3 China Market Size by Application
  • 8.3.1 China Cancer Biosimilar Monoclonal Antibodies Market Size by Application (2020-2031)
  • 8.3.2 China Cancer Biosimilar Monoclonal Antibodies Market Share by Application (2020-2031)

9 Asia (excluding China)

• 9.1 Asia Cancer Biosimilar Monoclonal Antibodies Market Size (2020-2031)
• 9.2 Asia Market Size by Type
  • 9.2.1 Asia Cancer Biosimilar Monoclonal Antibodies Market Size by Type (2020-2031)
  • 9.2.2 Asia Cancer Biosimilar Monoclonal Antibodies Market Share by Type (2020-2031)
• 9.3 Asia Market Size by Application
  • 9.3.1 Asia Cancer Biosimilar Monoclonal Antibodies Market Size by Application (2020-2031)
  • 9.3.2 Asia Cancer Biosimilar Monoclonal Antibodies Market Share by Application (2020-2031)
• 9.4 Asia Market Size by Region
  • 9.4.1 Asia Cancer Biosimilar Monoclonal Antibodies Market Size by Region: 2020 VS 2024 VS 2031
  • 9.4.2 Asia Cancer Biosimilar Monoclonal Antibodies Market Size by Region (2020-2031)
  • 9.4.3 Japan
  • 9.4.4 South Korea
  • 9.4.5 China Taiwan
  • 9.4.6 Southeast Asia
  • 9.4.7 India
  • 9.4.8 Australia

10 Middle East, Africa, and Latin America

• 10.1 Middle East, Africa, and Latin America Cancer Biosimilar Monoclonal Antibodies Market Size (2020-2031)
• 10.2 Middle East, Africa, and Latin America Market Size by Type
  • 10.2.1 Middle East, Africa, and Latin America Cancer Biosimilar Monoclonal Antibodies Market Size by Type (2020-2031)
  • 10.2.2 Middle East, Africa, and Latin America Cancer Biosimilar Monoclonal Antibodies Market Share by Type (2020-2031)
• 10.3 Middle East, Africa, and Latin America Market Size by Application
  • 10.3.1 Middle East, Africa, and Latin America Cancer Biosimilar Monoclonal Antibodies Market Size by Application (2020-2031)
  • 10.3.2 Middle East, Africa, and Latin America Market Share by Application (2020-2031)
• 10.4 Middle East, Africa, and Latin America Market Size by Country
  • 10.4.1 Middle East, Africa, and Latin America Cancer Biosimilar Monoclonal Antibodies Market Size by Country: 2020 VS 2024 VS 2031
  • 10.4.2 Middle East, Africa, and Latin America Cancer Biosimilar Monoclonal Antibodies Market Size by Country (2020-2031)
  • 10.4.3 Brazil
  • 10.4.4 Mexico
  • 10.4.5 Turkey
  • 10.4.6 Saudi Arabia
  • 10.4.7 Israel
  • 10.4.8 GCC Countries

11 Key Players Profiles

• 11.1 Amgen
  • 11.1.1 Amgen Company Details
  • 11.1.2 Amgen Business Overview
  • 11.1.3 Amgen Cancer Biosimilar Monoclonal Antibodies Introduction
  • 11.1.4 Amgen Revenue in Cancer Biosimilar Monoclonal Antibodies Business (2020-2025)
  • 11.1.5 Amgen Recent Development
• 11.2 Samsung Bioepis
  • 11.2.1 Samsung Bioepis Company Details
  • 11.2.2 Samsung Bioepis Business Overview
  • 11.2.3 Samsung Bioepis Cancer Biosimilar Monoclonal Antibodies Introduction
  • 11.2.4 Samsung Bioepis Revenue in Cancer Biosimilar Monoclonal Antibodies Business (2020-2025)
  • 11.2.5 Samsung Bioepis Recent Development
• 11.3 Sandoz
  • 11.3.1 Sandoz Company Details
  • 11.3.2 Sandoz Business Overview
  • 11.3.3 Sandoz Cancer Biosimilar Monoclonal Antibodies Introduction
  • 11.3.4 Sandoz Revenue in Cancer Biosimilar Monoclonal Antibodies Business (2020-2025)
  • 11.3.5 Sandoz Recent Development
• 11.4 Roche
  • 11.4.1 Roche Company Details
  • 11.4.2 Roche Business Overview
  • 11.4.3 Roche Cancer Biosimilar Monoclonal Antibodies Introduction
  • 11.4.4 Roche Revenue in Cancer Biosimilar Monoclonal Antibodies Business (2020-2025)
  • 11.4.5 Roche Recent Development
• 11.5 Merck
  • 11.5.1 Merck Company Details
  • 11.5.2 Merck Business Overview
  • 11.5.3 Merck Cancer Biosimilar Monoclonal Antibodies Introduction
  • 11.5.4 Merck Revenue in Cancer Biosimilar Monoclonal Antibodies Business (2020-2025)
  • 11.5.5 Merck Recent Development
• 11.6 Pfizer
  • 11.6.1 Pfizer Company Details
  • 11.6.2 Pfizer Business Overview
  • 11.6.3 Pfizer Cancer Biosimilar Monoclonal Antibodies Introduction
  • 11.6.4 Pfizer Revenue in Cancer Biosimilar Monoclonal Antibodies Business (2020-2025)
  • 11.6.5 Pfizer Recent Development
• 11.7 Mylan
  • 11.7.1 Mylan Company Details
  • 11.7.2 Mylan Business Overview
  • 11.7.3 Mylan Cancer Biosimilar Monoclonal Antibodies Introduction
  • 11.7.4 Mylan Revenue in Cancer Biosimilar Monoclonal Antibodies Business (2020-2025)
  • 11.7.5 Mylan Recent Development
• 11.8 BristolMyers Squibb
  • 11.8.1 BristolMyers Squibb Company Details
  • 11.8.2 BristolMyers Squibb Business Overview
  • 11.8.3 BristolMyers Squibb Cancer Biosimilar Monoclonal Antibodies Introduction
  • 11.8.4 BristolMyers Squibb Revenue in Cancer Biosimilar Monoclonal Antibodies Business (2020-2025)
  • 11.8.5 BristolMyers Squibb Recent Development
• 11.9 Celltrion
  • 11.9.1 Celltrion Company Details
  • 11.9.2 Celltrion Business Overview
  • 11.9.3 Celltrion Cancer Biosimilar Monoclonal Antibodies Introduction
  • 11.9.4 Celltrion Revenue in Cancer Biosimilar Monoclonal Antibodies Business (2020-2025)
  • 11.9.5 Celltrion Recent Development
• 11.10 Biocon
  • 11.10.1 Biocon Company Details
  • 11.10.2 Biocon Business Overview
  • 11.10.3 Biocon Cancer Biosimilar Monoclonal Antibodies Introduction
  • 11.10.4 Biocon Revenue in Cancer Biosimilar Monoclonal Antibodies Business (2020-2025)
  • 11.10.5 Biocon Recent Development
• 11.11 AbbVie
  • 11.11.1 AbbVie Company Details
  • 11.11.2 AbbVie Business Overview
  • 11.11.3 AbbVie Cancer Biosimilar Monoclonal Antibodies Introduction
  • 11.11.4 AbbVie Revenue in Cancer Biosimilar Monoclonal Antibodies Business (2020-2025)
  • 11.11.5 AbbVie Recent Development
• 11.12 Teva Pharmaceutical Industries
  • 11.12.1 Teva Pharmaceutical Industries Company Details
  • 11.12.2 Teva Pharmaceutical Industries Business Overview
  • 11.12.3 Teva Pharmaceutical Industries Cancer Biosimilar Monoclonal Antibodies Introduction
  • 11.12.4 Teva Pharmaceutical Industries Revenue in Cancer Biosimilar Monoclonal Antibodies Business (2020-2025)
  • 11.12.5 Teva Pharmaceutical Industries Recent Development
• 11.13 Henlius
  • 11.13.1 Henlius Company Details
  • 11.13.2 Henlius Business Overview
  • 11.13.3 Henlius Cancer Biosimilar Monoclonal Antibodies Introduction
  • 11.13.4 Henlius Revenue in Cancer Biosimilar Monoclonal Antibodies Business (2020-2025)
  • 11.13.5 Henlius Recent Development
• 11.14 Innovent Biologics
  • 11.14.1 Innovent Biologics Company Details
  • 11.14.2 Innovent Biologics Business Overview
  • 11.14.3 Innovent Biologics Cancer Biosimilar Monoclonal Antibodies Introduction
  • 11.14.4 Innovent Biologics Revenue in Cancer Biosimilar Monoclonal Antibodies Business (2020-2025)
  • 11.14.5 Innovent Biologics Recent Development
• 11.15 Qilu Pharmaceutical
  • 11.15.1 Qilu Pharmaceutical Company Details
  • 11.15.2 Qilu Pharmaceutical Business Overview
  • 11.15.3 Qilu Pharmaceutical Cancer Biosimilar Monoclonal Antibodies Introduction
  • 11.15.4 Qilu Pharmaceutical Revenue in Cancer Biosimilar Monoclonal Antibodies Business (2020-2025)
  • 11.15.5 Qilu Pharmaceutical Recent Development
• 11.16 Sunshine Guojian
  • 11.16.1 Sunshine Guojian Company Details
  • 11.16.2 Sunshine Guojian Business Overview
  • 11.16.3 Sunshine Guojian Cancer Biosimilar Monoclonal Antibodies Introduction
  • 11.16.4 Sunshine Guojian Revenue in Cancer Biosimilar Monoclonal Antibodies Business (2020-2025)
  • 11.16.5 Sunshine Guojian Recent Development
• 11.17 Bio-Thera Solutions
  • 11.17.1 Bio-Thera Solutions Company Details
  • 11.17.2 Bio-Thera Solutions Business Overview
  • 11.17.3 Bio-Thera Solutions Cancer Biosimilar Monoclonal Antibodies Introduction
  • 11.17.4 Bio-Thera Solutions Revenue in Cancer Biosimilar Monoclonal Antibodies Business (2020-2025)
  • 11.17.5 Bio-Thera Solutions Recent Development
• 11.18 Biotech Pharma
  • 11.18.1 Biotech Pharma Company Details
  • 11.18.2 Biotech Pharma Business Overview
  • 11.18.3 Biotech Pharma Cancer Biosimilar Monoclonal Antibodies Introduction
  • 11.18.4 Biotech Pharma Revenue in Cancer Biosimilar Monoclonal Antibodies Business (2020-2025)
  • 11.18.5 Biotech Pharma Recent Development
• 11.19 Junshi Biosciences
  • 11.19.1 Junshi Biosciences Company Details
  • 11.19.2 Junshi Biosciences Business Overview
  • 11.19.3 Junshi Biosciences Cancer Biosimilar Monoclonal Antibodies Introduction
  • 11.19.4 Junshi Biosciences Revenue in Cancer Biosimilar Monoclonal Antibodies Business (2020-2025)
  • 11.19.5 Junshi Biosciences Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

• 13.1 Research Methodology
  • 13.1.1 Methodology/Research Approach
    • 13.1.1.1 Research Programs/Design
    • 13.1.1.2 Market Size Estimation
    • 13.1.1.3 Market Breakdown and Data Triangulation
  • 13.1.2 Data Source
    • 13.1.2.1 Secondary Sources
    • 13.1.2.2 Primary Sources
• 13.2 Author Details
• 13.3 Disclaimer

List of Tables

Table 1. Global Cancer Biosimilar Monoclonal Antibodies Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031

Table 2. Key Players of Mouse Derived Monoclonal Antibody

Table 3. Key Players of Human Mouse Chimeric Monoclonal Antibody

Table 4. Key Players of Human Derived Monoclonal Antibody

Table 5. Key Players of Fully Human Derived Monoclonal Antibody

Table 6. Global Cancer Biosimilar Monoclonal Antibodies Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031

Table 7. Global Cancer Biosimilar Monoclonal Antibodies Market Size Growth Rate (CAGR) by Region (US$ Million): 2020 VS 2024 VS 2031

Table 8. Global Market Size by Region (2020-2031) & (US$ Million)

Table 9. Global Cancer Biosimilar Monoclonal Antibodies Market Share by Region (2020-2031)

Table 10. Market Trends

Table 11. Market Drivers

Table 12. Market Challenges

Table 13. Market Restraints

Table 14. Global Cancer Biosimilar Monoclonal Antibodies Revenue by Players (2020-2025) & (US$ Million)

Table 15. Global Cancer Biosimilar Monoclonal Antibodies Market Share by Players (2020-2025)

Table 16. Global Top Cancer Biosimilar Monoclonal Antibodies Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Cancer Biosimilar Monoclonal Antibodies as of 2024)

Table 17. Global Cancer Biosimilar Monoclonal Antibodies Industry Ranking 2023 VS 2024

Table 18. Global 5 Largest Players Market Share by Cancer Biosimilar Monoclonal Antibodies Revenue (CR5 and HHI) & (2020-2025)

Table 19. Global Key Players of Cancer Biosimilar Monoclonal Antibodies, Headquarters and Area Served

Table 20. Global Key Players of Cancer Biosimilar Monoclonal Antibodies, Product and Application

Table 21. Global Key Players of Cancer Biosimilar Monoclonal Antibodies, Date of Enter into This Industry

Table 22. Mergers & Acquisitions, Expansion Plans

Table 23. Global Market Size by Type (2020-2025) & (US$ Million)

Table 24. Global Cancer Biosimilar Monoclonal Antibodies Revenue Market Share by Type (2020-2025)

Table 25. Global Forecasted Market Size by Type (2026-2031) & (US$ Million)

Table 26. Global Cancer Biosimilar Monoclonal Antibodies Revenue Market Share by Type (2026-2031)

Table 27. Global Market Size by Application (2020-2025) & (US$ Million)

Table 28. Global Cancer Biosimilar Monoclonal Antibodies Revenue Market Share by Application (2020-2025)

Table 29. Global Forecasted Market Size by Application (2026-2031) & (US$ Million)

Table 30. Global Cancer Biosimilar Monoclonal Antibodies Revenue Market Share by Application (2026-2031)

Table 31. North America Market Size by Type (2020-2031) & (US$ Million)

Table 32. North America Market Size by Application (2020-2031) & (US$ Million)

Table 33. North America Cancer Biosimilar Monoclonal Antibodies Growth Rate (CAGR) by Country (US$ Million): 2020 VS 2024 VS 2031

Table 34. North America Market Size by Country (2020-2031) & (US$ Million)

Table 35. Europe Market Size by Type (2020-2031) & (US$ Million)

Table 36. Europe Market Size by Application (2020-2031) & (US$ Million)

Table 37. Europe Cancer Biosimilar Monoclonal Antibodies Growth Rate (CAGR) by Country (US$ Million): 2020 VS 2024 VS 2031

Table 38. Europe Market Size by Country (2020-2025) & (US$ Million)

Table 39. China Market Size by Type (2020-2031) & (US$ Million)

Table 40. China Market Size by Application (2020-2031) & (US$ Million)

Table 41. Asia Market Size by Type (2020-2031) & (US$ Million)

Table 42. Asia Market Size by Application (2020-2025) & (US$ Million)

Table 43. Asia Cancer Biosimilar Monoclonal Antibodies Growth Rate (CAGR) by Region (US$ Million): 2020 VS 2024 VS 2031

Table 44. Asia Market Size by Region (2020-2031) & (US$ Million)

Table 45. Middle East, Africa, and Latin America Market Size by Type (2020-2031) & (US$ Million)

Table 46. Middle East, Africa, and Latin America Market Size by Application (2020-2031) & (US$ Million)

Table 47. Middle East, Africa, and Latin America Cancer Biosimilar Monoclonal Antibodies Growth Rate (CAGR) by Country (US$ Million): 2020 VS 2024 VS 2031

Table 48. Middle East, Africa, and Latin America Market Size by Country (2020-2031) & (US$ Million)

Table 49. Amgen Company Details

Table 50. Amgen Business Overview

Table 51. Amgen Cancer Biosimilar Monoclonal Antibodies Product

Table 52. Amgen Revenue (2020-2025) & (US$ Million)

Table 53. Amgen Recent Development

Table 54. Samsung Bioepis Company Details

Table 55. Samsung Bioepis Business Overview

Table 56. Samsung Bioepis Cancer Biosimilar Monoclonal Antibodies Product

Table 57. Samsung Bioepis Revenue (2020-2025) & (US$ Million)

Table 58. Samsung Bioepis Recent Development

Table 59. Sandoz Company Details

Table 60. Sandoz Business Overview

Table 61. Sandoz Cancer Biosimilar Monoclonal Antibodies Product

Table 62. Sandoz Revenue (2020-2025) & (US$ Million)

Table 63. Sandoz Recent Development

Table 64. Roche Company Details

Table 65. Roche Business Overview

Table 66. Roche Cancer Biosimilar Monoclonal Antibodies Product

Table 67. Roche Revenue (2020-2025) & (US$ Million)

Table 68. Roche Recent Development

Table 69. Merck Company Details

Table 70. Merck Business Overview

Table 71. Merck Cancer Biosimilar Monoclonal Antibodies Product

Table 72. Merck Revenue (2020-2025) & (US$ Million)

Table 73. Merck Recent Development

Table 74. Pfizer Company Details

Table 75. Pfizer Business Overview

Table 76. Pfizer Cancer Biosimilar Monoclonal Antibodies Product

Table 77. Pfizer Revenue (2020-2025) & (US$ Million)

Table 78. Pfizer Recent Development

Table 79. Mylan Company Details

Table 80. Mylan Business Overview

Table 81. Mylan Cancer Biosimilar Monoclonal Antibodies Product

Table 82. Mylan Revenue (2020-2025) & (US$ Million)

Table 83. Mylan Recent Development

Table 84. BristolMyers Squibb Company Details

Table 85. BristolMyers Squibb Business Overview

Table 86. BristolMyers Squibb Cancer Biosimilar Monoclonal Antibodies Product

Table 87. BristolMyers Squibb Revenue (2020-2025) & (US$ Million)

Table 88. BristolMyers Squibb Recent Development

Table 89. Celltrion Company Details

Table 90. Celltrion Business Overview

Table 91. Celltrion Cancer Biosimilar Monoclonal Antibodies Product

Table 92. Celltrion Revenue (2020-2025) & (US$ Million)

Table 93. Celltrion Recent Development

Table 94. Biocon Company Details

Table 95. Biocon Business Overview

Table 96. Biocon Cancer Biosimilar Monoclonal Antibodies Product

Table 97. Biocon Revenue (2020-2025) & (US$ Million)

Table 98. Biocon Recent Development

Table 99. AbbVie Company Details

Table 100. AbbVie Business Overview

Table 101. AbbVie Cancer Biosimilar Monoclonal Antibodies Product

Table 102. AbbVie Revenue (2020-2025) & (US$ Million)

Table 103. AbbVie Recent Development

Table 104. Teva Pharmaceutical Industries Company Details

Table 105. Teva Pharmaceutical Industries Business Overview

Table 106. Teva Pharmaceutical Industries Cancer Biosimilar Monoclonal Antibodies Product

Table 107. Teva Pharmaceutical Industries Revenue (2020-2025) & (US$ Million)

Table 108. Teva Pharmaceutical Industries Recent Development

Table 109. Henlius Company Details

Table 110. Henlius Business Overview

Table 111. Henlius Cancer Biosimilar Monoclonal Antibodies Product

Table 112. Henlius Revenue (2020-2025) & (US$ Million)

Table 113. Henlius Recent Development

Table 114. Innovent Biologics Company Details

Table 115. Innovent Biologics Business Overview

Table 116. Innovent Biologics Cancer Biosimilar Monoclonal Antibodies Product

Table 117. Innovent Biologics Revenue (2020-2025) & (US$ Million)

Table 118. Innovent Biologics Recent Development

Table 119. Qilu Pharmaceutical Company Details

Table 120. Qilu Pharmaceutical Business Overview

Table 121. Qilu Pharmaceutical Cancer Biosimilar Monoclonal Antibodies Product

Table 122. Qilu Pharmaceutical Revenue (2020-2025) & (US$ Million)

Table 123. Qilu Pharmaceutical Recent Development

Table 124. Sunshine Guojian Company Details

Table 125. Sunshine Guojian Business Overview

Table 126. Sunshine Guojian Cancer Biosimilar Monoclonal Antibodies Product

Table 127. Sunshine Guojian Revenue (2020-2025) & (US$ Million)

Table 128. Sunshine Guojian Recent Development

Table 129. Bio-Thera Solutions Company Details

Table 130. Bio-Thera Solutions Business Overview

Table 131. Bio-Thera Solutions Cancer Biosimilar Monoclonal Antibodies Product

Table 132. Bio-Thera Solutions Revenue (2020-2025) & (US$ Million)

Table 133. Bio-Thera Solutions Recent Development

Table 134. Biotech Pharma Company Details

Table 135. Biotech Pharma Business Overview

Table 136. Biotech Pharma Cancer Biosimilar Monoclonal Antibodies Product

Table 137. Biotech Pharma Revenue (2020-2025) & (US$ Million)

Table 138. Biotech Pharma Recent Development

Table 139. Junshi Biosciences Company Details

Table 140. Junshi Biosciences Business Overview

Table 141. Junshi Biosciences Cancer Biosimilar Monoclonal Antibodies Product

Table 142. Junshi Biosciences Revenue (2020-2025) & (US$ Million)

Table 143. Junshi Biosciences Recent Development

Table 144. Research Programs/Design for This Report

Table 145. Key Data Information from Secondary Sources

Table 146. Key Data Information from Primary Sources

List of Figures

Figure 1. Global Cancer Biosimilar Monoclonal Antibodies Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)

Figure 2. Global Cancer Biosimilar Monoclonal Antibodies Market Share by Type: 2024 VS 2031

Figure 3. Mouse Derived Monoclonal Antibody Features

Figure 4. Human Mouse Chimeric Monoclonal Antibody Features

Figure 5. Human Derived Monoclonal Antibody Features

Figure 6. Fully Human Derived Monoclonal Antibody Features

Figure 7. Global Cancer Biosimilar Monoclonal Antibodies Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)

Figure 8. Global Cancer Biosimilar Monoclonal Antibodies Market Share by Application: 2024 VS 2031

Figure 9. Solid Tumor Treatment Case Studies

Figure 10. Hematological System Tumor Treatment Case Studies

Figure 11. Combination Therapy Case Studies

Figure 12. Cancer Biosimilar Monoclonal Antibodies Report Years Considered

Figure 13. Global Cancer Biosimilar Monoclonal Antibodies Market Size (US$ Million), Year-over-Year: 2020-2031

Figure 14. Global Cancer Biosimilar Monoclonal Antibodies Market Size, (US$ Million), 2020 VS 2024 VS 2031

Figure 15. Global Cancer Biosimilar Monoclonal Antibodies Market Share by Region: 2024 VS 2031

Figure 16. Global Cancer Biosimilar Monoclonal Antibodies Market Share by Players in 2024

Figure 17. Global Top Cancer Biosimilar Monoclonal Antibodies Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Cancer Biosimilar Monoclonal Antibodies as of 2024)

Figure 18. The Top 10 and 5 Players Market Share by Cancer Biosimilar Monoclonal Antibodies Revenue in 2024

Figure 19. North America Cancer Biosimilar Monoclonal Antibodies Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 20. North America Cancer Biosimilar Monoclonal Antibodies Market Share by Type (2020-2031)

Figure 21. North America Cancer Biosimilar Monoclonal Antibodies Market Share by Application (2020-2031)

Figure 22. North America Cancer Biosimilar Monoclonal Antibodies Market Share by Country (2020-2031)

Figure 23. United States Cancer Biosimilar Monoclonal Antibodies Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 24. Canada Cancer Biosimilar Monoclonal Antibodies Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 25. Europe Cancer Biosimilar Monoclonal Antibodies Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 26. Europe Cancer Biosimilar Monoclonal Antibodies Market Share by Type (2020-2031)

Figure 27. Europe Cancer Biosimilar Monoclonal Antibodies Market Share by Application (2020-2031)

Figure 28. Europe Cancer Biosimilar Monoclonal Antibodies Market Share by Country (2020-2031)

Figure 29. Germany Cancer Biosimilar Monoclonal Antibodies Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 30. France Cancer Biosimilar Monoclonal Antibodies Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 31. U.K. Cancer Biosimilar Monoclonal Antibodies Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 32. Italy Cancer Biosimilar Monoclonal Antibodies Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 33. Russia Cancer Biosimilar Monoclonal Antibodies Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 34. Nordic Countries Cancer Biosimilar Monoclonal Antibodies Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 35. China Cancer Biosimilar Monoclonal Antibodies Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 36. China Cancer Biosimilar Monoclonal Antibodies Market Share by Type (2020-2031)

Figure 37. China Cancer Biosimilar Monoclonal Antibodies Market Share by Application (2020-2031)

Figure 38. Asia Cancer Biosimilar Monoclonal Antibodies Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 39. Asia Cancer Biosimilar Monoclonal Antibodies Market Share by Type (2020-2031)

Figure 40. Asia Cancer Biosimilar Monoclonal Antibodies Market Share by Application (2020-2031)

Figure 41. Asia Cancer Biosimilar Monoclonal Antibodies Market Share by Region (2020-2031)

Figure 42. Japan Cancer Biosimilar Monoclonal Antibodies Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 43. South Korea Cancer Biosimilar Monoclonal Antibodies Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 44. China Taiwan Cancer Biosimilar Monoclonal Antibodies Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 45. Southeast Asia Cancer Biosimilar Monoclonal Antibodies Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 46. India Cancer Biosimilar Monoclonal Antibodies Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 47. Australia Cancer Biosimilar Monoclonal Antibodies Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 48. Middle East, Africa, and Latin America Cancer Biosimilar Monoclonal Antibodies Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 49. Middle East, Africa, and Latin America Cancer Biosimilar Monoclonal Antibodies Market Share by Type (2020-2031)

Figure 50. Middle East, Africa, and Latin America Cancer Biosimilar Monoclonal Antibodies Market Share by Application (2020-2031)

Figure 51. Middle East, Africa, and Latin America Cancer Biosimilar Monoclonal Antibodies Market Share by Country (2020-2031)

Figure 52. Brazil Cancer Biosimilar Monoclonal Antibodies Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 53. Mexico Cancer Biosimilar Monoclonal Antibodies Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 54. Turkey Cancer Biosimilar Monoclonal Antibodies Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 55. Saudi Arabia Cancer Biosimilar Monoclonal Antibodies Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 56. Israel Cancer Biosimilar Monoclonal Antibodies Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 57. GCC Countries Cancer Biosimilar Monoclonal Antibodies Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 58. Amgen Revenue Growth Rate in Cancer Biosimilar Monoclonal Antibodies Business (2020-2025)

Figure 59. Samsung Bioepis Revenue Growth Rate in Cancer Biosimilar Monoclonal Antibodies Business (2020-2025)

Figure 60. Sandoz Revenue Growth Rate in Cancer Biosimilar Monoclonal Antibodies Business (2020-2025)

Figure 61. Roche Revenue Growth Rate in Cancer Biosimilar Monoclonal Antibodies Business (2020-2025)

Figure 62. Merck Revenue Growth Rate in Cancer Biosimilar Monoclonal Antibodies Business (2020-2025)

Figure 63. Pfizer Revenue Growth Rate in Cancer Biosimilar Monoclonal Antibodies Business (2020-2025)

Figure 64. Mylan Revenue Growth Rate in Cancer Biosimilar Monoclonal Antibodies Business (2020-2025)

Figure 65. BristolMyers Squibb Revenue Growth Rate in Cancer Biosimilar Monoclonal Antibodies Business (2020-2025)

Figure 66. Celltrion Revenue Growth Rate in Cancer Biosimilar Monoclonal Antibodies Business (2020-2025)

Figure 67. Biocon Revenue Growth Rate in Cancer Biosimilar Monoclonal Antibodies Business (2020-2025)

Figure 68. AbbVie Revenue Growth Rate in Cancer Biosimilar Monoclonal Antibodies Business (2020-2025)

Figure 69. Teva Pharmaceutical Industries Revenue Growth Rate in Cancer Biosimilar Monoclonal Antibodies Business (2020-2025)

Figure 70. Henlius Revenue Growth Rate in Cancer Biosimilar Monoclonal Antibodies Business (2020-2025)

Figure 71. Innovent Biologics Revenue Growth Rate in Cancer Biosimilar Monoclonal Antibodies Business (2020-2025)

Figure 72. Qilu Pharmaceutical Revenue Growth Rate in Cancer Biosimilar Monoclonal Antibodies Business (2020-2025)

Figure 73. Sunshine Guojian Revenue Growth Rate in Cancer Biosimilar Monoclonal Antibodies Business (2020-2025)

Figure 74. Bio-Thera Solutions Revenue Growth Rate in Cancer Biosimilar Monoclonal Antibodies Business (2020-2025)

Figure 75. Biotech Pharma Revenue Growth Rate in Cancer Biosimilar Monoclonal Antibodies Business (2020-2025)

Figure 76. Junshi Biosciences Revenue Growth Rate in Cancer Biosimilar Monoclonal Antibodies Business (2020-2025)

Figure 77. Bottom-up and Top-down Approaches for This Report

Figure 78. Data Triangulation

Figure 79. Key Executives Interviewed